Magellan Health, Inc. (NASDAQ: MGLN) has long been the national leader in the use of digital innovation to help those struggling with various medical and behavioral conditions, including Substance Use Disorders (SUD). As a pioneer in the use of digital therapeutics and computerized cognitive behavioral therapy (CCBT), Magellan has engaged in a new initiative designed to measure clinical outcomes in patients with SUD by leveraging reSET®, the first ever FDA cleared prescription digital therapeutic from PEAR Therapeutics.
PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that it has successfully closed a $50 million Series B financing led by Temasek.
CNS Summit, a community at the intersection of life sciences and technology, will bring together key figures leading the digital transformation of the life science industry.
Pear Therapeutics, the leader in prescription digital therapeutics, today announced that it has received an Expedited Access Pathway (EAP) designation from the U.S. Food and Drug Administration (FDA) for its reSET-O™ Prescription Digital Therapeutic, the first of its kind designed for treating Opioid Use Disorder (OUD).
Pear Therapeutics, the leader in a new era of prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Pear’s De Novo request, allowing the company to market reSET® for the treatment of patients with substance use disorder (SUD) under a new class of treatment. This is the first time that the FDA has cleared a Prescription Digital Therapeutic with claims to improve clinical outcomes in a disease.
Digital therapy could soon be prescribed and reimbursed like a pharmaceutical drug for patients with chronic substance use disorder. “This could be a watershed moment for digital health,” said Corey McCann, MD, PhD, chief executive officer of Pear Therapeutics, the developer of the software.
Pear Therapeutics (PEAR), the creator of prescription digital therapies called eFormulationsTM, announced today that it has successfully closed on a $20M equity financing. 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners led the round, with participation from Bridge Builders Collaborative and several additional investors.
Pear Therapeutics aims to use drugs with an app to help addicts kick the habit ~ The Boston Business Journal Article